Lung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

Size: px
Start display at page:

Download "Lung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium"

Transcription

1 Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

2 Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000 50,000 Number of patients 100,000 80,000 60,000 40,000 20, Number of patients 40,000 30,000 20,000 10, Age category (years) Age category (years) All-male Lung cancer-male All-women Lung cancer-women All-male Lung cancer-male All-women Lung cancer-women Incidence Mortality National Program of Cancer Registries (NPCR)

3 2 30 Early-stage non-small cell lung cancer

4 Surgery Author (year) N pts Stage Positive prognostic factors Outcome ~ Age Chang (07) IA Tumor size (<2.0 cm) 5-year survival Gender (women) 52 vs. 65% Age (< 67 years) Resection (anatomical) Ou (07) IA-IB Age Gender (women) Socio-economic class Surgical treatment Histological differentation Tumor size (< 4 cm) (IB) Anatomical location (IB) Schneider (08) NA ECOG PS Operative mortality 3.0% <65 years 7.9% years 10.5% >75 years 5-year survival = 3 30

5 Radiotherapy Treatment Overall survival (%) No Conventional RT Stereotactic RT 6 14 (5-year) 34 (3-year) 70 (5-year) Haasbeek CJ et al. Oncologist

6 Adjuvant cisplatin-based chemotherapy Trial ALPI ANITA BLT IALT JBR.10 N patients 1.101* Eligibility Stage I-IIIA IB-IIIA I-III I-III IB-II Upper age limit None 75 None 75 None Total cisplatin dose (mg/m²) / vinorelbine No Yes Yes Yes Yes + other agents Yes No Yes Yes No Hazard ratio p < Difference at 5 years (%) No 8.6 No * 1,209, minus 108 excluded from one center Fruh M et al. J Clin Oncol

7 Adjuvant cisplatin-based chemotherapy: overall survival by treatment and age All Elderly > 70 years HR death 0.86; 95% CI HR death 0.90; 95% CI Fruh M et al. J Clin Oncol

8 Early-stage NSCLC in elderly patients Surgery = standard of care Feasible Higher operative mortality in case of co-morbidity Radiotherapy Valuable option in selected patients Adjuvant chemotherapy No survival benefit >70 years 7 30

9 8 30 Advanced non-small cell lung cancer

10 First-line treatment: comparison youngelderly Author (year) Treatment RR(%) MOS (months) Qol/Tox Y E Y E Kelly (2001) Pacli-carbo NR NR = Vino-cis Langer (2002) Pacli-carbo + G-CSF > hemato Eto+ cis Schiller (2002) Pacli + cis > grade 4 tox Gem + cis Doc + cis Pacli + carbo Lilenbaum (2005) Pacli Pacli + carbo Sandler (2005) Pacli + carbo > tox with bev Pacli + carbo + bev RR: response rate; MOS: median overall survival; Qol: quality of life; Tox: toxicity; Carbo: carboplatin; Pacli: paclitaxel; Cis: cisplatin; Bev: bevacizumab; Eto: etoposide; G-CSF: granulocyte-colony stimulating factor; Eto: etoposide; Gem: gemcitabine, Doc: docetaxel, Y: younger: E: elderly; NR: not reported Avery et al. Cancer Treat Rev

11 First-line treatment in elderly patients: single agent Author (year) Treatment N pts RR(%) MOS (wks) Qol/Toxicity Elvis (99) BSC Vino Vino Kudoh (06) Vino D Doc Lilenbaum (07) Doc q 1w x3 q wks > w Doc q 3 wks Leong (07) Gem = Vino Doc RR: response rate; MOS: median overall survival; wks: weeks; Qol: quality of life: BSC: best supportive care; Vino: vinorelbine; Doc: docetaxel; Gem: gemcitabine; : better than; =: equal to; > more toxic than 10 30

12 First-line treatment in elderly patients: combinations Author (year) Treatment N pts RR(%) MOS (wks) Qol/Toxicity Frasci (00) Vino Vino +Gem Vino+ Gem Gridelli (03) Vino = Gem Vino+ Gem Comella (04) Gem +Pacli mo = Gem + Vino mo Pacli mo Gem mo Hainsworth (07) Doc = Doc + Gem 22 Gridelli (07) Pem = Pem + Gem RR: response rate; MOS: median overall survival; wks: weeks; Qol: quality of life: Vino: vinorelbine; Gem: gemcitabine; Doc: docetaxel; Pem: pemetrexed; : better with; =: equal to: > more toxic; mo: months 11 30

13 First-line treatment in elderly patients: platinum compounds/targeted agents Author (year) Treatment N pts RR(%) MOS (wks) QolToxicity Chen (06) Carbo + Pacli Cis > Carbo Cis + Pacli Ramalingam (08) Carbo + Pacli B Carbo + Pacli + B Reck (09) Cis + Gem NA B Cis + Gem + B * NA RR: response rate; MOS: median overall survival; wks: weeks; Qol: quality of life: Carbo: carboplatin; Pacli: paclitaxel; Cis: cisplatin; Gem: Gemcitabine; B: bevacizumab; : worse with: > more toxic 12 30

14 Second-line treatment in elderly patients Author (year) Treatment N pts RR(%) MOS (wks) Qol/Toxicity Wheatley (08) Erlotinib E Placebo 51 NA 20 RR: response rate; MOS: median overall survival; wks: weeks; Qol: quality of life: E: erlotinib: paclitaxel; Cis: cisplatin; : higher than 13 30

15 Advanced NSCLC in elderly patients First-line chemotherapy Single-agent vinorelbine, gemcitabine, or taxanes (paclitaxel and docetaxel) are first-line treatment options Non-platinum combinations vs single agent Higher response rates and/or disease-free survival Similar median overall survival or 1-year survival rates Slightly more toxic Platinum combinations Cisplatin more toxic than carboplatin Targeted agents Bevacizumab more toxic Second-line chemotherapy Targeted agents are treatment option 14 30

16 15 30 Small cell lung cancer: limited disease

17 First-line treatment Author (year) Age N pts Treatment MST 5YS p (years) (months) (%) Siu (96) < CAV/PE + RT 8 NS > Jara (99) <70 20 PE + RT 12.3 NS > Yuen (00) < PE + either BID/QD RT 19 NS > Ludbrook (03) <65 55 CT + RT 37*.003 > * > * Schild (04) < PE + either BID/QD RT 22 NS > BID: twice-daily; CAV: cyclophosphamide + doxorubicin + vincristine; CT: chemotherapy; HDEP: highdose epirubicin + cisplatin; MST: median survival time; NS: not significant; PE: cisplatin + etoposide; QD: once-daily; RT = radiotherapy;*: 2-year survival, 5YS: 5-year survival Rossi A et al. Oncologist

18 First-line treatment: chemoradiation Author (year) Age N pts Treatment RR MST (years) (%) (months) Murray (98) >70 55 CAV (1 cycle) + PE (1 cycle) Gy Jeremic (98) cpe (2 cycles) ACC HFX ACC HFX = accelerated hyperfractionated radiotherapy; CAV = cyclophosphamide + doxorubicin + vincristine; cpe = carboplatin + oral etoposide; RR: response rate; MST = medial survival time; PE = cisplatin + etoposide Rossi A et al. Oncologist

19 First-line treatment: chemoradiation Role of thoracic irradiation 13 randomized trials 2140 patients 3-year survival 8.9 % CT alone 14.3% CT+RT Relative risk of death < 55 years: 0.72 (95%CI ) > 70 years: 1.07 (95%CI ) Pignon et al. N Engl J Med

20 First-line treatment: single agent Author (year) Age N pts Treatment RR MST (years) (%) (months) Smit (89) > Oral etoposide Bork (97) > Oral etoposide 7 30 Oral etoposide 7.5 Quoix (92) > Epirubicin 50 Cerny (88) > Teniposide Tummarello (92) > Teniposide Cascinu (97) > Teniposide 30 8 MST = median survival time; NR = not reported; RR = response rate Rossi A et al. Oncologist

21 First-line treatment: carboplatin combinations Author (year) Age N pts Treatment RR MST (years) (%) (months) Evans (95) > carbo + eto a Matsui (98) > carbo + eto a Okamoto (99) > carbo + eto Goss (91) > carbo + teni 72 a: oral etoposide; carbo: carboplatin; eto: etoposide; RR: response rate; MST = median survival time; teni: teniposide Rossi A et al. Oncologist

22 First-line treatment: single agent versus combinations Study (year) N pts Age, years Treatment RR MS (range) (%) Medical Research (35 82) Oral etoposide 45 * 130 d* Council (96) 68 (45 83) IV Chemotherapy d (EV or CAV) Souhami (97) (50 86) Oral etoposide 33* 4.8 m* 67 (49 80) IV Chemotherapy m (PE or CAV) Yrs: years; RR: response rate; MS: median survival; IV: intravenous; EV: Etoposide and vincristine; CAV: Cyclophosphamide, doxorubicin, vincristine; PE: Cisplatin and etoposide; *: p<

23 Indirect and Subgroup Analyses First-line treatment: pancranial radiotherapy Characteristic Relative risk of death Relative risk of brain metastases Age (years) (95% CI) (95% CI) < ( ) 0.55 ( ) yr 0.90 ( ) 0.49 ( ) >65 yr 0.79 ( ) 0.37 ( ) Auperin A et al. N Engl J Med

24 Limited disease SCLC in elderly patients Chemoradiation Same benefit in elderly as in younger patients Higher toxicity The role of thoracic radiotherapy seems less important in older patients Single agent chemotherapy is active Carboplatin combinations are feasible Combination chemotherapy results in higher responses and longer median survival than single agent Prophylactic pancranial radiotherapy is effective in reducing brain metastasis 23 30

25 24 30 Small cell lung cancer: extensive disease

26 First-line treatment: single agent Author (year) Age N pts Treatment RR MST (years) (%) (months) Smit (89) > Oral etoposide 63 9 Bork (97) > Oral etoposide a Oral etoposide b 7.2 Quoix (92) > Epirubicin 45 Cerny (88) > Teniposide Tummarello (92) > Teniposide 49 9 Cascinu (97) > Teniposide 10 6 a: prolonged administration; b: every 3 weeks; MST = median survival time; NR = not reported; RR = response rate Rossi A et al. Oncologist

27 First-line treatment: combinations Author (year) Age N pts Treatment RR MST (years) (%) (months) Gridelli (02) > Carbo + vino +G-CSF Westeel (89) >65 41 PAVE carbo: carboplatin; vino: vinorelbine; G-CSF: granulocyte colony stimulating factor; PAVE: cisplatin, doxorubicin; vincristine, etoposide; RR: response rate; MST = median survival time Rossi A et al. Oncologist

28 Indirect and Subgroup Analyses First-line treatment: pancranial radiotherapy Irradiation (N = 143); median age (years) (range): 62 (37-75); control (N = 143); median age (years) (range): 63 (39 75) Slotman B et al. N Engl J Med

29 Extensive disease SCLC in elderly patients Single agent chemotherapy is active Platinum combinations are feasible Prophylactic pancranial radiotherapy is effective 28 30

30 Treatment of lung cancer in the elderly Life expectancy based on Age Co-morbidity Geriatric frailty ADL dependency > 3 co-morbidities Geriatric syndrome - + Life expectancy > cancer survival Life expectancy < cancer survival Contra-indications anti-cancer treatment - Risk and benefits anti-cancer treatment IADL Nutritional status Social structure + No influence of cancer on QoL Follow up Cancer influences QoL Palliative care Risks < Benefits Risks > Benefits Anti-cancer treatment 29 30

31 30 30

Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials

Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized

More information

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage

More information

1st-line Chemotherapy for Advanced disease

1st-line Chemotherapy for Advanced disease SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS

More information

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative

More information

Thoracic and head/neck oncology new developments

Thoracic and head/neck oncology new developments Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening

More information

THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra,

THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, Slovakia Lancet. 1966;2(7471):979-86. First standard treatment:

More information

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive

More information

LUNG CANCER TREATMENT: AN OVERVIEW

LUNG CANCER TREATMENT: AN OVERVIEW LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor

More information

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts

More information

Adjuvant Chemotherapy

Adjuvant Chemotherapy State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant

More information

doi: /theoncologist

doi: /theoncologist Treatment of Small Cell Lung Cancer in the Elderly Antonio Rossi, Paolo Maione, Giuseppe Colantuoni, Ciro Guerriero, Carmine Ferrara, Filomena Del Gaizo, Dario Nicolella and Cesare Gridelli The Oncologist

More information

Maintenance paradigm in non-squamous NSCLC

Maintenance paradigm in non-squamous NSCLC Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons

More information

Optimal Application of Adjuvant Therapy in NSCLC

Optimal Application of Adjuvant Therapy in NSCLC Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo

More information

Slide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3

Slide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3 Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial

More information

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug

More information

Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico

Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II

More information

ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine

ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from

More information

Treatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)

Treatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias

More information

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David

More information

Câncer de Pulmão Não Pequenas Células

Câncer de Pulmão Não Pequenas Células Câncer de Pulmão Não Pequenas Células Carboplatina + Paclitaxel Paclitaxel: 200mg/m 2 IV D1 Carboplatina: AUC 6 IV D1 a cada 21 dias X 4 ciclos Ref. (1) Vinorelbina + Cisplatina Vinorelbina: 25mg/m 2 IV

More information

Small Cell Lung Cancer What we have now?

Small Cell Lung Cancer What we have now? Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,

More information

Stato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY

Stato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Stato dell arte del trattamento del microcitoma Antonio ROSSI, MD Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Truly has become small. Last session/day in all meetings One chemo

More information

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy

More information

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens 1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days

More information

Lung cancer update 2007

Lung cancer update 2007 Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis

More information

Systemic therapy in early stage NSCLC. Disclosures

Systemic therapy in early stage NSCLC. Disclosures Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany

More information

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern

More information

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease

More information

Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?

Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology

More information

LUNG. Tumour Group: Regimen name / acronym. Place in therapy. Induction chemotherapy. Regimen name / acronym. Place in therapy

LUNG. Tumour Group: Regimen name / acronym. Place in therapy. Induction chemotherapy. Regimen name / acronym. Place in therapy Tumour Group: LUNG Non-small cell lung cancer Adjuvant Vinorelbine PO* / Cisplatin 1 x x First line Vinorelbine IV / Cisplatin x First line Vinorelbine IV / Carboplatin x cisplatin Vinorelbine PO* / Cisplatin

More information

Heather Wakelee, M.D.

Heather Wakelee, M.D. Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.

More information

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive

More information

Author(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3)

Author(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3) Title Trends in chemotherapy for elderly non-small-cell lung cancer. Author(s) Kim, Young Hak; Yoh, Kiyotaka; Niho Ohmatsu, Hironobu; Kubota, Kaoru; N Citation Respiratory medicine (2010), 104(3) Issue

More information

EGFR inhibitors in NSCLC

EGFR inhibitors in NSCLC Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance

More information

The Evolving Role of Adjuvant Therapies

The Evolving Role of Adjuvant Therapies Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives

More information

Lung Cancer Epidemiology. AJCC Staging 6 th edition

Lung Cancer Epidemiology. AJCC Staging 6 th edition Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON

More information

Adjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia

Adjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents

More information

Adjuvant therapy of NSCLC: where to go from here?

Adjuvant therapy of NSCLC: where to go from here? SAMO Winter Workshop on Chest Tumours Adjuvant therapy of NSCLC: where to go from here? J Vansteenkiste Dept Pulmonology Leuven Lung Cancer Group > adjuvant therapy ± 1,200,000 lung cancers worldwide >80%

More information

Locally Advanced NSCLC and its management in the Elderly. Dr Laura Pemberton Consultant Clinical Oncologist, Christie Hospital, UK

Locally Advanced NSCLC and its management in the Elderly. Dr Laura Pemberton Consultant Clinical Oncologist, Christie Hospital, UK Locally Advanced NSCLC and its management in the Elderly Dr Laura Pemberton Consultant Clinical Oncologist, Christie Hospital, UK Topics covered Concurrent Chemoradiotherapy (concrt) in elderly Radiotherapy

More information

The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer

The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer Evidence-based Series # 7-13-3 EDUCATION AND INFORMATION 2013 The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer Members of the Lung Cancer

More information

Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy

Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University

More information

ESMO Preceptorship Programme NSCLC Singapore 15 November 2017

ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA

More information

LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University

LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies

More information

Cooperative Group Update - Japan; JCOG & WJOG -

Cooperative Group Update - Japan; JCOG & WJOG - Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center

More information

Management of Lung Cancer in Older Adults

Management of Lung Cancer in Older Adults Management of Lung Cancer in Older Adults Arti Hurria, MD; Mark G. Kris, MD ABSTRACT Lung cancer is the leading cause of cancer death in the United States. At the time of diagnosis, most patients are older

More information

Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)

Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic

More information

Chemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002

Chemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002 Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women

More information

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000

More information

Heterogeneity of N2 disease

Heterogeneity of N2 disease Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity

More information

Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer

Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL

More information

Practice changing studies in lung cancer 2017

Practice changing studies in lung cancer 2017 1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received

More information

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)

More information

Systemic Management of Malignant Pleural Mesothelioma

Systemic Management of Malignant Pleural Mesothelioma ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 15.June-19.June 2018 Belgrade, Serbia Systemic Management of Malignant Pleural Mesothelioma Dragana Jovanovic University Hospital

More information

Personalized Medicine for Advanced NSCLC in East Asia

Personalized Medicine for Advanced NSCLC in East Asia Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,

More information

PRACTICE GUIDELINE SERIES

PRACTICE GUIDELINE SERIES ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian

More information

The road less travelled: what options are available for patients with advanced squamous cell carcinoma?

The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting

More information

SCLC: Developments in systemic treatment

SCLC: Developments in systemic treatment SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment

More information

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common

More information

Weitere Kombinationspartner der Immunotherapie

Weitere Kombinationspartner der Immunotherapie 1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for

More information

Adjuvant radiotherapy for completely resected early stage NSCLC

Adjuvant radiotherapy for completely resected early stage NSCLC Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique

More information

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy

More information

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease, Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000

More information

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University 2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling

More information

Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab

Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori

More information

1st line chemotherapy and contribution of targeted agents

1st line chemotherapy and contribution of targeted agents ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

CANCER TREATMENT REGIMENS

CANCER TREATMENT REGIMENS CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation

More information

MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf

MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance

More information

Treatment of Older Adult Patients with Non-Small Cell Lung Cancer

Treatment of Older Adult Patients with Non-Small Cell Lung Cancer LIVE WEBINARS Treatment of Older Adult Patients with Non-Small Cell Lung Cancer Presented by: Neelesh Sharma, MD, PhD Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland

More information

Treatment of PS 2 Patients with Advanced NSCLC:

Treatment of PS 2 Patients with Advanced NSCLC: Treatment of PS 2 Patients with Advanced NSCLC: Current State of the Art Corey J Langer MD, FACP Director, Thoracic Oncology Abramson Cancer Center Professor of Medicine University of Pennsylvania Philadelpia,

More information

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity

More information

Recent Therapeutic Advances for Thoracic Malignancies

Recent Therapeutic Advances for Thoracic Malignancies Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation

More information

Incorporating Immunotherapy into the treatment of NSCLC

Incorporating Immunotherapy into the treatment of NSCLC Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute

More information

Sao Paulo, Abril 2014

Sao Paulo, Abril 2014 Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use

More information

Advances in Chemotherapy for Non-Small Cell Lung Cancer

Advances in Chemotherapy for Non-Small Cell Lung Cancer Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in

More information

Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors

Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis

More information

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome

More information

in combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4

in combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4 Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small

More information

1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC

1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC 1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science

More information

State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?

State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA

More information

Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer

Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence

More information

Tough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France

Tough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Tough to treat tumors in elderly Pancreatic cancer: how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Top 5 causes of cancer death / age Cancer Statistics in the USA 2008, CA

More information

Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,

More information

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly

More information

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

Management of advanced non small cell lung cancer

Management of advanced non small cell lung cancer Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict

More information

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.

More information

Debate on stage III NSCLC: The role of systemic therapy

Debate on stage III NSCLC: The role of systemic therapy 1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases

More information

Adjuvant Radiotherapy for completely resected NSCLC

Adjuvant Radiotherapy for completely resected NSCLC Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local

More information

Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs

Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm

More information

ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA

ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO

More information

ASCO Highlights Lung Cancer

ASCO Highlights Lung Cancer ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical

More information

Clinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia

Clinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential

More information

Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer

Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March

More information

Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D.

Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery, Kanagawa

More information

NEJ, Sendai North East Japan. TCOG, Tokyo Tokyo Clinical Oncology G.

NEJ, Sendai North East Japan. TCOG, Tokyo Tokyo Clinical Oncology G. Slide 1 Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery,

More information

Lung cancer is the leading cause of cancer mortality in both

Lung cancer is the leading cause of cancer mortality in both ORIGINAL ARTICLE Chemotherapy in Patients 80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and Paul J. Hesketh, MD,* Rogerio C. Lilenbaum, MD, Kari Chansky, MS, Afshin Dowlati,

More information